Back to top
more

Phibro Animal Health (PAHC)

(Delayed Data from NSDQ)

$25.55 USD

25.55
357,276

+1.70 (7.13%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $25.57 +0.02 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New Animal Health Products, Vaccine Sales Support PAHC Stock

by Zacks Equity Research

Phibro Animal Health is focusing on new developments, incremental registrations and volumes of existing vaccine technologies.

Should You Continue to Hold TMO Stock in Your Portfolio?

by Zacks Equity Research

Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

PAHC or ABT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PAHC vs. ABT: Which Stock Is the Better Value Option?

Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Hold IART Stock in Your Portfolio Now

by Zacks Equity Research

Integra's strong growth in the Tissue Technologies and CSS business segment bolsters investors' confidence in the stock.

Is EXAS Stock a Smart Addition to Your Portfolio Right Now?

by Zacks Equity Research

Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.

ACB Stock Likely to Gain From Genome BC-Funded Aroma Research Project

by Zacks Equity Research

Aurora Cannabis' new collaboration on the Genome BC-Funded Project addresses distinct cannabis aromas.

Is it the Right Time to Hold EW Stock in Your Portfolio Now?

by Zacks Equity Research

Edward Lifesciences' Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.

Here's Why You Should Retain BRKR Stock in Your Portfolio Now

by Zacks Equity Research

Bruker's robust growth potential across its Nano segment is encouraging. Yet, unfavorable currency movement is likely to pose a challenge.

Here's Why You Should Add BSX Stock to Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive MedSurg market share gain.

TMO Stock Likely to Gain From New International CorEvitas AD Registry

by Zacks Equity Research

Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.

Global Expansion, Strategic Innovations Aid Boston Scientific Stock

by Zacks Equity Research

We are impressed with BSX's recent acquisitions that have added numerous products with immense potential.

t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock

by Zacks Equity Research

By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.

TMO Stock Gains From Innovation Amid Macroeconomic Issues

by Zacks Equity Research

Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

by Zacks Equity Research

BIO strategically expands its ddPCR platform while eyeing global expansion and benefiting from its clinical diagnostics arm.

RMD Stock Likely to Gain From Enhanced Digital Sleep Health Solutions

by Zacks Equity Research

ResMed introduces digital and personalized solutions designed to improve sleep health.

Urmimala Biswas headshot

3 MedTech Stocks to Buy as Monetary Policy Eases

by Urmimala Biswas

Here, we pick three MedTech stocks, VCYT, BSX and PAHC, which are anticipated to gain strongly in 2024 from the loosening of monetary policy.

Positive Trial Outcome for PulseSelect PFA Likely to Boost MDT Stock

by Zacks Equity Research

Medtronic presents new clinical data on the PulseSelect PFA System and marks its launch in Japan.

Phibro (PAHC) Up 2.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QGEN Stock to Gain From New IVDR Win for QIAstat-Dx Systems and Panels

by Zacks Equity Research

QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays.

MDT Stock Might Gain From Expanded AiBLE Ecosystem and New Partnership

by Zacks Equity Research

Medtronic expands AiBLE spine surgery ecosystem with new technologies and a partnership with Siemens Healthineers.

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Industry Outlook Highlights Boston Scientific, Baxter International, Haemonetics and Phibro Animal Health

by Zacks Equity Research

Boston Scientific, Baxter International, Haemonetics and Phibro Animal Health are part of the Zacks Industry Outlook article.

Exclusive Partnership With Pair Eyewear Likely to Support EYE Stock

by Zacks Equity Research

National Vision's America's Best stores become the exclusive retail partner of Pair Eyewear.